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A B S T R A C T
Background
Hyaluronidase has been used over many decades as an adjunct to local anaesthetic solution to improve the speed of onset of eye
blocks and to provide better akinesia and analgesia. With the evolution of modern eye surgery techniques, fast onset and akinesia are
not essential requirements anymore. The assumption that the addition of hyaluronidase to local anaesthetic injections confers better
analgesia for the patient needs to be examined. There has been no recent systematic review to provide evidence that hyaluronidase
actually improves analgesia.
Objectives
To ascertain if adding hyaluronidase to local anaesthetic solutions for use in ophthalmic anaesthesia in adults results in a reduction of
perceived pain during the operation and to assess harms, participant and surgical satisfaction, and economic impact.
Search methods
We carried out systematic searches in Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, and four
other databases in June 2017. We searched the trial registers at www.ISRCTN.com, ClinicalTrials.gov and www.clinicaltrialsregister.eu
for relevant trials. We imposed no language restrictions.
Selection criteria
We included randomized controlled trials (RCTs) that evaluated the effect of hyaluronidase on pain experienced by adults during
intraocular surgery using a rating scale.
Data collection and analysis
Two review authors (HR and KA) independently extracted data and assessed methodological quality using standard procedures as
expected by Cochrane.
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Main results
We included seven trials involving 500 participants that studied the effect of hyaluronidase on intraoperative pain. Four of the seven
trials with 289 participants reported the primary outcome in a dichotomous manner, and we proceeded to meta-analyse the findings
which showed a moderate heterogeneity that could not be explained (I2 = 41% ). The pooled risk ratio (RR) for these four trials was
0.83 with the 95% confidence interval ranging from 0.48 to 1.42. The reduction in intraoperative pain scores in the hyaluronidase
group were not statistically significant. Among the three trials that reported the primary outcome in a continuous manner, the presence
of missing data made it difficult to conduct a meta-analysis. To further explore the data, we imputed standard deviations for the other
studies from another included RCT (Sedghipour 2012). However, this resulted in substantial heterogeneity between study estimates
(I² = 76% ). The lack of reported relevant data in two of the three remaining trials made it difficult to assess the direction of effect in a
clinical setting.
Overall, there was no statistical difference regarding the intraoperative reduction of pain scores between the hyaluronidase and control
group. All seven included trials had a low risk of bias.
According to GRADE, we found the quality of evidence was low and downgraded the trials for serious risk of inconsistency and
imprecision. Therefore, the results should be analysed with caution.
Participant satisfaction scores were significantly higher in the hyaluronidase group in two high quality trials with 122 participants.
Surgical satisfaction was also superior in two of three high quality trials involving 141 participants. According to GRADE, the quality
of evidence was moderate for participant and surgical satisfaction as the trials were downgraded for imprecision due to the small sample
sizes. The risk of bias in these trials was low.
There was no reported harm due to the addition of hyaluronidase in any of the studies. No study reported on the cost of hyaluronidase
in the context of eye surgery.
Authors’ conclusions
The effects of adding hyaluronidase to local anaesthetic fluid on pain outcomes in people undergoing eye surgery are uncertain due to
the low quality of evidence available. A well designed RCT is required to address inconsistency and imprecision among the studies and
to determine the benefit of hyaluronidase to improve analgesia during eye surgery. Participant and surgical satisfaction is higher with
hyaluronidase compared to the control groups, as demonstrated in moderate quality studies. There was no harm attributed to the use
of hyaluronidase in any of the studies. Considering that harm was only rarely defined as an outcome measure, and the overall small
number of participants, conclusions cannot be drawn about the incidence of harmful effects of hyaluronidase. None of the studies
undertook cost calculations with regards to use of hyaluronidase in local anaesthetic eye blocks.
P L A I N L A N G U A G E S U M M A R Y
Addition of hyaluronidase to local anaesthetic eye blocks to reduce pain during eye surgery in adults.
Review question
We reviewed the evidence on the effectiveness of adding hyaluronidase to local anaesthetic eye block solutions (a numbing medicine
injected into the eye to block nerves) to reduce pain and increase participant and surgical satisfaction during eye surgery in adults. We
also looked for reports on side effects and cost.
Background
Hyaluronidase is an enzyme (a protein that regulates a chemical reaction in the body) that helps the spread of local anaesthetic through
the tissues around the eye. It is widely used as an additive to local anaesthetic eye blocks to give more rapid onset of anaesthesia and reduce
or block movement of the eye (called akinesia). With modern eye surgery techniques, fast onset and akinesia are no longer essential
requirements, and often surgery can be undertaken pain-free with topical (on the surface of the eye) anaesthesia alone. Hyaluronidase
has been associated with infrequent side effects. Therefore, the use of hyaluronidase needs to be justified, which was the aim of this
review.
Search date
The review is current to 30 June 2017.
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Study characteristics
We included seven randomized controlled trials (clinical studies where people are randomly put into one of two or more treatment
groups) in our review. These involved 500 adults undergoing eye surgery under local anaesthesia. We looked at any additional effect
of adding hyaluronidase to local anaesthetic on the pain experienced during eye surgery. We also looked at participant and surgical
satisfaction scores and if any harms were reported after using hyaluronidase in the injection solution. None of the studies reported on
costs.
Key results
Of the seven included trials, we pooled the results of four trials (289 participants) as the results were reported in a similar manner.
They found that addition of hyaluronidase did not significantly reduce pain during surgery. Among the three remaining trials (211
participants) lack of data reporting in two trials made it difficult to pool the results. The overall result of looking at all these trials
together suggests there was no significant reduction of pain with using hyaluronidase in eye nerve blocks.
We found moderate quality evidence from two trials (122 participants) to suggest that addition of hyaluronidase increased partici-
pant satisfaction scores. Three studies involving 141 participants looked at surgical satisfaction, which was reported as superior with
hyaluronidase in the two larger studies and not significantly different in one small study (19 participants). None of the included studies
reported any harmful effects of hyaluronidase.
Quality of evidence
The included trials that reported on pain during surgery were at low risk for bias. The overall quality of evidence was low because of
variations in the effect on pain reduction. We contacted all trial authors to request more information on the trials, but the data were
not available.
Moderate quality studies reported greater participant and surgical satisfaction with hyaluronidase.
Analgesia alone does not take into account the full spectrum of the beneficial effects of hyaluronidase. Patient comfort with the eye
surgery is also likely to be improved by a speedy onset and reduced eye movements due to hyaluronidase.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Use of hyaluronidase as an adjunct to local anaesthetic eye blocks to reduce intraoperative pain in adults
Patients or population: adults (aged ≥ 18 years) undergoing ophthalm ic surgery under local anaesthet ic eye blocks.
Setting: hospitals in the UK (4), Germany (1), Brazil (1) and Iran (1).
Intervention: local anaesthet ic eye blocks containing hyaluronidase.
Comparison: local anaesthet ic eye blocks containing no hyaluronidase.
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with no
hyaluronidase
Risk with
hyaluronidase
Intraoperative pain (re-
ported dichotomous)
assessed with: ana-
logue rat ing scales
No follow-up - mea-
sured on day of surgery.
RR 0.83
(0.48 to 1.42)
289
(4 RCTs)
⊕⊕©©
Low1,2
-
301 per 1000 250 per 1000
(145 to 428)
Intraoperative pain (re-
ported continuous)
assessed with: ana-
logue rat ing scales
No follow-up - mea-
sured on day of surgery.
3 trials looked at ef fect of hyaluronidase on re-
duct ion of intraoperat ive pain measured by rat-
ing scales. Results were reported as cont inu-
ous data. 2 studies did not provide the SMD,
which measures the ef fect in a clinical set-
t ing, the results could not be meta-analysed
and hence were reported narrat ively (Khandwala
2008; Rowley 2000). Among the 3 trials covering
211 part icipants (Khandwala 2008: Mean dif fer-
ence 0.70; Rowley 2000: Mean dif ference 0.31;
Sedghipour 2012: Mean dif ference -1.10), only
the Sedghipour study with 42 part icipants, which
is a high quality study, showed a stat ist ically
signif icant (at the 5 % level) reduct ion in pain in
the hyaluronidase group (P = 0.04). The remain-
ing 2 studies with 169 part icipants showed no
- 211
(3 RCTs)
⊕⊕©©
Low3
-
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stat ist ically signif icant (at the 5 % level) reduc-
t ion of pain intraoperat ively with hyaluronidase
(Khandwala 2008: P = 0.5; Rowley 2000: n.s).
These studies were also of high quality and low
risk of bias. Khandwala and colleagues had an
unclear attrit ion bias as 1/ 10 part icipants in the
treatment group was dropped af ter randomiza-
t ion with no clear explanat ion
Incidence of harm None of the studies reported harms in relat ion to
hyaluronidase
- (0 studies) - -
Participant satisfac-
tion
assessed with: scoring
system
No follow-up - mea-
sured on day of surgery.
Signif icant ly better sat isfact ion in these well
designed studies with low risk of bias (Remy
2008; Sedghipour 2012). The studies included
122 part icipants and showed higher sat isfact ion
scores in the treatment group (P < 0.05)
- 122
(2 RCTs)
⊕⊕⊕©
Moderate4
-
Surgical satisfaction
assessed with: scoring
system
No follow-up - mea-
sured on the day of
surgery.
Surgical sat isfact ion was reportedly superior
with hyaluronidase in the larger 2 studies (Remy
2008: P < 0.001; Sedghipour 2012: P = 0.02)
and not signif icant ly dif f erent in 1 small study
(Khandwala 2008: P = 0.96).
- 141
(3 RCTs)
⊕⊕⊕©
Moderate4
-
Economic outcomes or
cost calculations
None of the included studies reported economic
outcomes or cost calculat ions
- (0 RCTs) - -
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; n.s: not stat ist ically signif icant; RCT: randomized controlled trial; RR: risk rat io; SMD: standardized mean dif ference.
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded one level due to marked heterogeneity with a calculated I2 > 50%.
2Downgraded one level for imprecision due to wide 95% conf idence intervals, ref lect ing uncertainty in the direct ion of ef fect
est imate.
3Downgraded one level for imprecision and inconsistency in measurement, lack of data and small sample size.
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4Downgraded one level because of imprecision secondary to small sample size.
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B A C K G R O U N D
Description of the condition
Local anaesthesia for ophthalmic surgery can be provided by re-
gional injection block or topical anaesthesia alone. The most fre-
quently used anaesthetic injections are retrobulbar, peribulbar and
sub-Tenon’s block.
During a local anaesthetic injection for ophthalmic surgery, the
objective is to deliver local anaesthetic fluid to the sensory and mo-
tor nerve fibres in the orbit. There is a large variation of techniques,
anaesthetic mixtures and instruments in use to achieve this. Some
of these techniques have been compared in Cochrane Reviews; for
example, peribulbar versus retrobulbar block (Alhassan 2015), and
topical anaesthesia alone versus sub-Tenon’s block (Guay 2015).
Schein 2000 undertook a comprehensive systematic review of
anaesthetic interventions.
Unfortunately, there is always a proportion of blocks that fail to
provide adequate analgesia or akinesia. To improve the quality
of the anaesthetic block, various adjuncts to the local anaesthetic
fluid have been introduced.
Description of the intervention
Atkinson 1949 first described the addition of hyaluronidase to
local anaesthetic fluid with the intention of improving the speed
of onset of analgesia and akinesia. Subsequently, hyaluronidase has
commonly been added to local anaesthetic injection fluid for this
purpose.
How the intervention might work
For any local anaesthetic block to work, the local anaesthetic fluid
needs to spread through the orbital cavity to reach the relevant
motor and sensor fibres. A complex system of connective tissue
membranes divides the orbital space, thereby impeding the spread
of local anaesthetic fluid (Koornneef 1988).
Buhren 2016 described the molecular mechanisms of how
hyaluronidase spreads through this connective tissue barrier, in
the most recent review on this topic. The main components of
connective tissue are the fibrous proteins collagen and elastin as
well as proteoglycans located in the extracellular matrix. Gly-
cosamine-glycans attach to proteoglycans in a characteristic man-
ner giving the connective tissue its viscoelastic properties. The
most common glycosamine-glycan is hyaluronic acid, it is a lin-
ear glycosaminoglycan disaccharide composed of alternating units
of N-acetyl-D-glucosamine and D-glucuronic acid via alternating
ß(1-4) andß(1-3) glycosidic bonds.Hyaluronidase (hyaluronoglu-
cosaminidase) is an enzyme that facilitates the spread of local anaes-
thetic fluid through connective tissue by degrading hyaluronic acid
into smaller fragments and hydrolyzing the disaccharides at hex-
osaminidic ß(1-4) linkages.
Meyer 1934 first extracted hyaluronidase. Preparations contain
purified ovine testicular hyaluronidase as a dehydrated steril-
ized solid for reconstitution before use. Brand names of ani-
mal-derived hyaluronidase include Hydase, Vitrase, Amphadase,
Wydase and Hyalase. Apart from a preparation of ovine testicular
hyaluronidase, a recombinant human hyaluronidase is also avail-
able as Hylenex. It is produced by genetically engineered Chinese
hamster ovary cells containing a DNA plasmid encoding for a
soluble fragment of human hyaluronidase (Hylenex® Prescribing
Information 2016). The exact chemical structure of this enzyme
is unknown. The approximate molecular weight is 61,000 daltons
(Borders 1968).
Hyaluronidase also alters the pH of a local anaesthetic due to the
presence of phosphate buffers within the preparation. The pH of
plain bupivacaine solution is changed from5.3 to 6.3 following the
addition of hyaluronidase, and it may maintain local anaesthetic
solubility during the process of alkalinization (Roberts 1993). This
alkalinization may also explain any improved anaesthesia and aki-
nesia.
A reduction in time to onset of surgical anaesthesia is consid-
ered desirable to facilitate patient throughput. The action of
hyaluronidase may promote rapid onset of anaesthesia and akine-
sia. The minimum and maximum effective doses of hyaluronidase
are unknown. The doses used range from 0.75 IU/mL to 300 IU/
mL (Dempsey 1997).
Why it is important to do this review
We conducted this systematic review to explore the uncertainty
about the benefits of using hyaluronidase in local anaesthetic mix-
tures to provide analgesia during eye surgery. There is considerable
variation of practice, and the studies in this area show conflicting
results.
Furthermore, the use of hyaluronidase increases the cost of the
anaesthetic and has been associated with adverse allergic reactions
in a small number of cases. For example, Kempeneers 1992, de-
scribed five people who developed an orbital pseudotumour as
a complication of retrobulbar anaesthesia. Allergic reactions can
range from local reactions to anaphylactic (systemic allergy) shock.
Whenhyaluronidase is added to a local anaesthetic agent, thewider
spread of the local anaesthetic solution also increases its absorption
and removal in the bloodstream. This shortens the duration of ac-
tion of the local anaesthetic and tends to increase the incidence of
systemic reactions. Some hyaluronidase products contain bovine
ingredients, and due to the theoretical concerns about transmis-
sible spongiform encephalopathies, the World Health Organiza-
tion (WHO) issued guidelines regarding the use of bovine materi-
als in the manufacture of biological and pharmaceutical products
(WHO 2010).
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The absence of hyaluronidase in ophthalmic regional blockade
has also been associated with adverse events. An interruption in
hyaluronidase supply was associated with a cluster of postoperative
diplopia (double vision) Brown 1999. It was postulated that the
absence of hyaluronidase caused the local anaesthetic to loculate
in close proximity to the extraocular muscles and cause clinically
significant myotoxicity.When hyaluronidase was unavailable once
again in 2000, Brown 2001 published a repeated cluster of diplopia
cases. The omissionof hyaluronidase in local anaesthesia fluid leads
to clinically important rises in intraocular pressure. This is thought
to be due to the decreased removal anddispersal of local anaesthetic
fluid from the periocular compartment (Dempsey 1997).
Therefore, use of hyaluronidasemust be justified, and datamust be
available for clinicians and patients to make an informed decision
regarding the efficacy of hyaluronidase addition. The results of this
review should allow justification (or not) for the use of adjuvant
hyaluronidase to improve the quality of anaesthesia and analgesia.
O B J E C T I V E S
To ascertain if adding hyaluronidase to local anaesthetic solutions
for use in ophthalmic anaesthesia in adults results in a reduction
of perceived pain during the operation and to assess harms, par-
ticipant and surgical satisfaction and economic impact.
(See Differences between protocol and review).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included:
1. Randomized controlled trials (RCTs) and quasi-randomized
controlled clinical trials either published or unpublished;
2. Studies if they compared equal volumes and concentrations
of local anaesthetic with and without adjuvant hyaluronidase
administered with the injection;
3. Studies when other adjuvants such as adrenaline were used,
only if the adjuvant was present in both the control and
hyaluronidase intervention;
Types of participants
We included:
1. Adults (aged 18 years and older) presenting for ophthalmic
surgery under ophthalmic anaesthetic block;
2. Participants receiving sub-Tenon’s, peribulbar, retrobulbar
or other types of local anaesthetic;
3. Participants receiving sedation but documented this fact;
We excluded:
1. Participants receiving adnexal surgery and any other eye
surgery that was not intraocular;
2. Participants who received general anaesthesia;
Types of interventions
Ophthalmic local anaesthetic blocks comparing adjuvant
hyaluronidase to an otherwise equal anaesthetic and surgery with-
out hyaluronidase.
We considered any dose of hyaluronidase in the intervention group
and any dose or type of local anaesthetic agent.
We included studies that used any number of injections to anaes-
thetise the eye if the number of injections was equal in the treat-
ment and control groups.
Types of outcome measures
Primary outcomes
1. Intraoperative pain, as measured by analogue rating scales.
We excluded studies that reported pain, but did not measure
pain formally using analogue rating scales, as they did not
provide sufficiently useful information on the outcome. We
excluded studies if they reported that ’supplementary injections’
were primarily given to achieve akinesia, for example, if a certain
immobility score was not reached.
(See Differences between protocol and review).
Secondary outcomes
1. Incidence of harm (reported as a narrative).
2. Participant and surgical satisfaction, as documented by
scoring systems.
3. Economic outcomes or cost calculations (reported as a
narrative).
Search methods for identification of studies
Electronic searches
We carried out systematic searches in:
1. The Cochrane Central Register of Controlled Trials(
CENTRAL, 2007 Issue 6; Appendix 1);
2. Ovid MEDLINE (1946 to 30 June 2017; Appendix 2);
3. Ovid Embase (1947 to 30 June 2017; Appendix 3);
4. Web of Science (1900 to 30 June 2017; Appendix 4);
5. Scopus (1823 to 30 June 2017; Appendix 5);
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6. CINAHL Plus (EBSCOhost, 1937 to 30 June 2017;
Appendix 6);
7. LILACS (1982 to 30 June 2017; Appendix 7);
We broke down our research question into four key search-
able concepts: “ Eye,” “Surgery,” “ Local Anaesthesia” and
“Hyaluronidase”.This strategy ensured that we retrieved studies
on eye surgery where local anaesthesia was applied along with
hyaluronidase. We conducted searches for each concept using free
text terms and MeSH terms wherever possible. When we carried
out free text searches, we applied synonyms, derivative forms and
singular/plural forms for each concept. Detailed search steps are
documented in the ’Appendices’.
We applied no language restrictions.
Searching other resources
We searched the reference lists of all eligible trials and reviews and
used any trials that fit the inclusion criteria.
We searched the registers at www.controlled-trials.com,
www.ISRCTN.com and www.clinicaltrialsregister.eu for relevant
trials.
We contacted specialists in the field, authors of the included trials
and pharmaceutical manufacturers for any unpublished data.
The search of these other resources was completed by 30 June
2017.
Data collection and analysis
Selection of studies
Two review authors (KA and HR) independently reviewed the
trials identified from the search strategy, removed duplicates
and documented the reason for each trial being excluded (see
Characteristics of excluded studies table). We resolved any dis-
agreements with the studies by input from a third review au-
thor CB). We presented information regarding methods, partici-
pants, setting, interventions and outcomes in the Characteristics
of included studies table. Where studies had multiple publica-
tions, we planned to collate the reports of the same study so that
each study, rather than each report, was the unit of interest for
the review, and such studies had a single identifier with multiple
references. (See Differences between protocol and review).
Data extraction and management
Two review authors (KA and HR) independently extracted and
collected data on a paper form. After initial piloting this form was
assessed and agreed for usability. A copy of this form is inAppendix
8. We (KA and HR) resolved any discrepancies in data extracted
by discussion with a third review author (CB) as a final arbiter.
In the case of additional information being required, HR or KA
contacted the authors of the relevant trial.
Assessment of risk of bias in included studies
To assess the risk of bias, two review authors (KA and HR) inde-
pendently assessed the studies included in the review according to
the criteria described by Higgins 2011. We assessed the following
aspects as being at either ’low risk’, ’high risk’ or ’unclear risk’ of
bias. We assessed the risk of bias for the following components of
each trial.
1. Random sequence generation (selection bias).
2. Allocation concealment (selection bias).
3. Masking of participants and personnel (performance bias).
4. Masking of outcome assessment (detection bias).
5. Incomplete outcome data (attrition bias).
6. Selective reporting (reporting bias).
7. Other bias.
We included a ’Risk of bias’ table as part of the Characteristics of
included studies table based on Cochrane’s tool for assessing the
risk of bias, from the Cochrane Handbook for Systematic Reviews
of Interventions (Chapter 8:Higgins 2011). See Appendix 8 (data
collection form) and Appendix 10 (’Risk of bias’ table).
Measures of treatment effect
Intraoperative pain
We noted intraoperative pain measured using visual analogue
scales (VAS) or verbal rating scales (VRS) when available and in-
terpreted them as continuous data. We used the greatest intraop-
erative score reported. We planned to use the standardized mean
difference (SMD) as an effect measure and 95% confidence inter-
vals (CIs) to allow for the fact that different studies might have
used different scales. However, because the only studies detected
used the same scaling method, there was no need to use the SMD.
If authors documented non-normality of their data, we extracted
medians and interquartile ranges and collated this information.
(See Differences between protocol and review).
In the case of absolute numbers of participants experiencing pain
where a rating scale was used but reported in a dichotomous man-
ner (data as pain or no pain), we used risk ratios (RR) with 95%CI
as a measure of effect. We collated this information and reported
it. While there was evidence of moderate heterogeneity (I2 = 41%)
we presented a meta-analysis but urge caution interpreting this.
To avoid multiplicity, we restricted meta-analyses to the primary
outcomes but thiswouldnot be at the cost of presenting the totality
of evidence should there be more RCTs providing information
with regards to adverse effects.
Incidence of harm
We would have reported adverse events due to the use of
hyaluronidase (e.g. allergic reactions) as a narrative, but as ex-
pected, there were no reports of such adverse events, probably be-
cause of their rarity and the relatively small number of participants
in each trial.
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Participant and surgical satisfaction
We reported participant and surgical satisfaction scores narratively.
We would also have noted as narrative if other validated tools had
been used.
Economic outcomes or cost calculation
We planned to report economic outcomes or cost calculations
narratively.
Unit of analysis issues
We anticipated that most trials would involve one eye per partici-
pant, and even if both eyes were included, our outcomes were pri-
marily measured at the participant rather than eye level. It was very
unlikely that both eyes were operated on simultaneously with dif-
ferent anaesthetic procedures. (See Differences between protocol
and review).
Dealing with missing data
We contacted authors and asked them to provide missing data.
We imposed a time limit of two months and follow-up on one
occasion. Irrespective of the type of data, we reported dropout rates
in the ’Risk of bias’ tables within the Characteristics of included
studies table and noted whether or not authors had compared
characteristics of participants who had complete data sets against
those that did not. We investigated studies that had missing data,
whether or not imputing for missing cases impacted greatly on the
interpretation of findings. We attempted to impute the data, but
the values obtained would not be consistently reflected within the
trials due to the variation in sample size.
Assessment of heterogeneity
We assessed all studies for clinical andmethodological heterogene-
ity.We examined the I2 statistic and it’s 95% CI to assess inconsis-
tency between studies as recommended by theCochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011). We used
the thresholds advised by Higgins 2011, for the interpretation of
the I2 statistic. We found substantial inconsistency in our primary
outcome when assessed as a continuous score (I2 = 76%) but less
when assessed as a dichotomousmeasure (I2 =41%).We attempted
to investigate causes for this by exploring factors such as the type
and duration of surgery, anaesthetic intervention (hyaluronidase
dosage, type and volume of anaesthetic fluid) but the number of
studies contributing to the meta-analysis was small. Despite the
heterogeneity, we presented a meta-analysed outcome for the di-
chotomized outcome but urge caution in its interpretation.
Assessment of reporting biases
We assessed publication bias and small study effects in a qualitative
manner using a funnel plot. We planned to test for funnel plot
asymmetry if there had been a meta-analysis with more than 10
studies included.
Data synthesis
We performed the analysis using Review Manager 5 (RevMan
2014).
While we found some evidence of heterogeneity (for the dichoto-
mous outcome), we meta-analysed results using a random-effects
model as per our original intentions. A random-effects model was
chosen because we believe that each trial estimates an intervention
effect that follows a distribution across studies.
Subgroup analysis and investigation of heterogeneity
We planned no subgroup analyses.
Sensitivity analysis
We carried out sensitivity analyses to explore the robustness of
the results to key methodological decisions that we made in our
review. We examined whether or not excluding studies at risk of
bias impacted on our findings, and since we had missing data,
we attempted to impute and examine whether or not analysing
intention-to-treat data differed considerably from the available
case meta-analysis.
GRADE assessment of quality of evidence
We adopted the GRADE system postprotocol (Rüschen 2013)
to rate the quality of evidence for each outcome (Guyatt 2011).
GRADE assessment classifies the quality of evidence into four cat-
egories; high, moderate, low and very low. The overall assessment
considers the study design, risk of bias, imprecision, inconsistency,
indirectness, publication bias, large effect size, dose-response ef-
fect and presence of confounding factors to rate the evidence. We
applied the principles of GRADE to assess the quality of evidence
specific to each outcome in our review.
1. Intraoperative pain, as measured by analogue rating scales.
2. Incidence of harm.
3. Participant and surgical satisfaction, as documented by
scoring systems.
4. Economic outcomes or cost calculations.
The GRADE software from GRADEpro GDT generated the
’Summary of findings’ table. The GRADE approach ensures the
confidence which one can have in the estimate of effect from the
outcomes being assessed in the included studies.
(See Differences between protocol and review).
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R E S U L T S
Description of studies
See Characteristics of included studies and Characteristics of
excluded studies tables.
Results of the search
See Figure 1 for the study flow diagram.
11Use of hyaluronidase as an adjunct to local anaesthetic eye blocks to reduce intraoperative pain in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 1. Study flow diagram.
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We identified 942 references after removal of duplicates. Two re-
view authors (HR and KA) independently read and analysed the
abstracts of all references and if needed, full papers. We excluded
779 references as clearly irrelevant to the review. We obtained the
full papers for the remaining 163 references and again analysed
them independently. We identified 18 trials, and 11 trials were
further excluded for reasons documented in the ’Characteristics
of excluded studies’ table. The review includes seven trials.
Included studies
Design
We included seven RCTs published from 1995 to 2012 with 500
participants (Bowman 1997; Brydon 1995; Khandwala 2008;
Remy2008;Rowley 2000; Sedghipour 2012; Shiroma2002).One
study was published in Portuguese and translated into English
(Shiroma 2002).
Characteristics of study population
The review included 500 participants.The participants were adults
(aged 18 years or older) presenting for ophthalmic surgery under-
going a retrobulbar, peribulbar or sub-Tenon block. The mean age
in the studies ranged from 66 to 77 years. Studies were balanced
with regards to gender.
Setting
Four studies were conducted in the UK (Bowman 1997; Brydon
1995; Khandwala 2008; Rowley 2000). The remaining three stud-
ies were based in Germany (Remy 2008), Brazil (Shiroma 2002),
and Iran (Sedghipour 2012).
Intervention
The seven trials studied the effect of adding hyaluronidase to a
local anaesthetic mixture with the primary outcome measure of
reduction of intraoperative pain. The participants were divided
into a treatment group (hyaluronidase) and a control group (no
hyaluronidase). The doses of hyaluronidase used ranged from 15
IU/mL to 150 IU/mL.
All seven trials assessed pain objectively using either the VAS or the
VRS and compared a groupwith hyaluronidase to a group without
hyaluronidase (Bowman 1997; Brydon 1995; Khandwala 2008;
Remy 2008; Rowley 2000; Sedghipour 2012; Shiroma 2002).
One trial included three arms in their study looking at effects of no
hyaluronidase and effects of hyaluronidase at 50 IU/mL and 150
IU/mL (Brydon 1995). We combined the results of the groups
with different doses of hyaluronidase and compared them with
the no hyaluronidase group.
Funding sources
Two trials reported no conflict of interest and received no funding
support for the trials (Khandwala 2008; Remy 2008). There was
no clear documentation of reported conflict of interest or funding
support from the remaining five trials (Bowman 1997; Brydon
1995; Rowley 2000; Sedghipour 2012; Shiroma 2002).
We attempted to contact the authors of all the trials for additional
data but received no clarification.
For more details about the included trials, see the Characteristics
of included studies table.
Excluded studies
We excluded 11 studies after analysis (Berg 2001; Crawford 1994;
Guise 1999; House 1991; Johansen 1993; Lange 1989; Moharib
2002; Morsman 1992; Ramanathan 1999; Sarvela 1992; Soares
2002).
Three studies reported that “supplementary injections” were pri-
marily given to achieve akinesia, for example, if a certain immobil-
ity score was not reached. Pain during surgery was not assessed or
reported specifically.(Crawford 1994; House 1991; Soares 2002).
One study did not mask the relevant part of the trial (Morsman
1992).
Four studies did not assess pain or discomfort using a rating scale,
and the inclusion criteria were ultimately not met (Berg 2001;
Guise 1999; Johansen 1993; Moharib 2002). We excluded these
studies because they did not measure the outcome measure of
“pain by rating scale”. They reported an unstructured description
of pain. This is unlikely to provide useful information about the
levels of pain during the operation.
One study was published as a poster presentation (Ramanathan
1999). We contacted the author for more details about random-
ization, masking and results but none was made available.
We excluded one study because there was no randomization, this
was not immediately obvious (Lange 1989).
We excluded one study because the relevant part of the study was
not randomized and only compared different concentrations of
hyaluronidase (Sarvela 1992).
See Characteristics of excluded studies table.
Awaiting classification
We found no studies awaiting classification.
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Ongoing studies
We identified no ongoing studies.
Risk of bias in included studies
We judged the quality of studies according to the methods de-
scribed in the Cochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2011). Overall, the selected studies were of
low risk; however, there was a lack of concise information in the
methodology of randomization andwithdrawal description. Please
refer to Figure 2 and Figure 3 for a summary of risk of bias as-
sessment for the selected studies and a ’Risk of bias’ graph that
represents the studies.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
All seven included studies reported that allocation was random-
ized, but only three studies provided any detail about themethodof
random allocation (Khandwala 2008; Rowley 2000; Sedghipour
2012). These three studies were at low risk of allocation bias. The
studies used random number tables, stratified lottery system or
computer generated randomization. The remaining four studies
were at unclear risk of bias.
With regard to allocation concealment, four of the seven studies
used “coded syringes” (Khandwala 2008; Remy 2008; Rowley
2000; Sedghipour 2012). We classed these at low risk of bias, but
an experienced operator might have recognized the formation of
tiny bubbles in the mixture indicating hyaluronidase content.
Most studies implied that participants, personnel and assessors
were unaware of the composition of the anaesthetic solution be-
cause the syringes were coded by an uninvolved third party, but
exact details were rarely given.
In this context, only one study used a placebo control, with inactive
Hyalase (Remy 2008).
Blinding
Five studies were classified as low risk for performance and de-
tection bias (Bowman 1997; Khandwala 2008; Rowley 2000;
Sedghipour 2012; Shiroma 2002). These studies had described
double masking where neither the participant nor the caregiver
was aware of the contents of the syringe. The outcome assessors
were also masked, which further reduced the risk of bias by mask-
ing.
Incomplete outcome data
Withdrawal of participants after randomization was rarely re-
ported in detail.
Six studies were at low risk as there was a description of no with-
drawals; therefore, we had more confidence in the intention-to-
treat analysis for these studies (Bowman 1997; Brydon 1995;
Remy 2008; Rowley 2000; Sedghipour 2012; Shiroma 2002).
Of the included seven studies, one described the withdrawal of
participants after randomization (Khandwala 2008). One partici-
pant was withdrawn from the treatment group due to incomplete
data. No further details were given. Considering the low number
of participants in this trial (10 in each of two arms) the exclusion
may represent bias.
Selective reporting
We found all seven studies at low risk of reporting bias. Pain was
stated as an outcome measure at the start of the trials. We did
not attempt to obtain research protocols (Bowman 1997; Brydon
1995; Khandwala 2008; Remy 2008; Rowley 2000; Sedghipour
2012; Shiroma 2002).
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Other potential sources of bias
We found no other potential sources of bias.
Effects of interventions
See: Summary of findings for the main comparison Use of
hyaluronidase as an adjunct to local anaesthetic eye blocks to
reduce intraoperative pain in adults
Primary outcomes
1. Intraoperative pain, as measured by analogue rating scales
Seven trials with 500 participants looked at the effect of
hyaluronidase on the reduction of intraoperative pain. Four of
these trials with 289 participants reported intraoperative pain in a
dichotomous manner (Bowman 1997; RR 0.82, 95% CI 0.38 to
1.75; Brydon 1995; RR 1.00, 95% CI 0.20 to 5.00; Remy 2008;
RR 0.47, 95% CI 0.24 to 0.92; Shiroma 2002; RR 1.45, 95% CI
0.70 to 3.00). We calculated the (RR) as a measure of effect. The I
2 statistic was 41%, which represents moderate heterogeneity. We
proceeded to meta-analyse the results and found that the pooled
RR was 0.83 (95% CI 0.48 to 1.42). Therefore, there was no sta-
tistically significant reduction of pain scores in the hyaluronidase
group.
Three studies involving 211 participants reported pain objectively
using rating scales and presented continuous data (Khandwala
2008; Rowley 2000; Sedghipour 2012). Sedghipour 2012 de-
scribed 42 participants in a high quality study and provided SDs
for their data. They found a significant reduction of pain in the
hyaluronidase group (P = 0.04). The other two trials did not re-
port SDs (Khandwala 2008; Rowley 2000). We interchanged the
SDs from Sedghipour 2012, but this resulted in significant het-
erogeneity among the studies (I²= 76%), so we did not perform a
meta-analysis. See Figure 4 and Figure 5.
Figure 4. Forest plot of comparison: 1 Hyaluronidase versus control, outcome: 1.1 Intraoperative pain
(measured by analogue rating scales; reported continuous).
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Figure 5. Forest plot of comparison: 1 Hyaluronidase versus control, outcome: 1.2 Intraoperative pain
(measured by analogue rating scales; reported dichotomous).
Looking at the overall studies taking into account the results of
the meta-analysis and the individual studies that reported the con-
tinuous outcome, there was no statistically significant reduction
in intraoperative pain with hyaluronidase in the local anaesthetic
mixture. However, this has to be interpreted with caution.
We adopted the GRADEpro method of analysing the quality
of evidence and produced Summary of findings for the main
comparison. We found the quality of studies was low. We down-
graded the quality of evidence due to concerns regarding incon-
sistency in the direction and magnitude of effect across the studies
(I2 = 41% and 76%). We looked at the individual studies for fac-
tors that could have contributed to the heterogeneity and found
that there was no wide variability between characteristics of par-
ticipants, interventions and outcome measures. We tried to es-
tablish if the heterogeneity was due to the dose of hyaluronidase,
the volume of injection or number of participants, but there was
insufficient data provided to enable a valid analysis. The level of
imprecision was another reason for downgrading the quality of
evidence. Only Rowley 2000, provided a rationale for the selected
sample size that would yield the specific effect measure.
Secondary outcomes
1. Incidence of harm
None of the included studies measured or reported the incidence
of harm from hyaluronidase.
2. Participant and surgical satisfaction, as documented by
scoring systems
Two studies analysing 122 participants looking at participant sat-
isfaction reported that the investigator and participant assessment
scores were significantly higher in the hyaluronidase group (P <
0.05)(Remy 2008; Sedghipour 2012). The studies assessed satis-
faction in different ways so prohibiting meta-analysis Remy 2008
used a five level VAS to assess participant efficacy and tolerability
at the end of surgery and at the final visit, while Sedghipour 2012
captured data as a dichotomous ’satisfied’ or ’unsatisfied’. Using
the GRADE system to assess the quality of evidence, we found the
studies were of moderate quality with low risk of bias.
We found three studies involving 141 participants that mea-
sured surgical satisfaction scores (Khandwala 2008; Remy 2008;
Sedghipour 2012). Sedghipour 2012 reported that surgical sat-
isfaction with intraoperative anaesthesia was 85.7% in the
hyaluronidase group compared to 52.5% in the control group (P
= 0.02). Remy 2008 reported a P value of less than 0.001 for
surgical satisfaction in the hyaluronidase group. Khandwala 2008
found no difference in the quality of the surgical field between
groups (P = 0.96). These studies assessed surgeon satisfaction as
they had assessed participant satisfaction while Khandwala 2008
simply asked surgeons to rate surgical conditions on a VAS from
0 (worst) to 10 (best). Since each had assessed satisfaction using
a different method, no meta-analysis was conducted. There was
low risk of bias with regards to the method of randomization with
Sedghipour 2012, and there was incomplete outcome data report-
ing with Khandwala 2008. Overall, we found the quality of evi-
dence with these two studies to be moderate. See Figure 2.
3. Economic outcomes or cost calculations
None of the included studies reported on the economic impact of
using hyaluronidase.
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D I S C U S S I O N
The use of hyaluronidase in ophthalmic surgery remains a topic of
debate. The perceived advantages of adding hyaluronidase include
shortened time to onset of the block and improved akinesia, and as
investigated in this review: analgesia. The apparent disadvantages
of hyaluronidase include the additional cost and possible adverse
reactions.
Most modern surgical techniques are no longer essentially depen-
dent on akinesia. Anaesthesia itself is readily provided by eye blocks
without hyaluronidase. Even topical anaesthesia is often deemed
sufficient during routine cataract surgery. We systematically re-
viewed the literature on the benefits of hyaluronidase for analgesia
in ophthalmic surgery.
Summary of main results
We reviewed evidence from seven RCTs involving 500 partici-
pants regarding the reduction of pain during intraocular surgery by
adding hyaluronidase to the local anaesthetic fluid. We found that
the reduction of intraoperative pain by hyaluronidase was not sta-
tistically significant. The quality of evidence was low. We assessed
the literature in this field as having a low risk of bias, but we had
concerns regarding heterogeneity across the studies. With regards
to the outcomes of participant and surgeon satisfaction, the mod-
erate quality studies show an advantage of using hyaluronidase.
(See Summary of findings for the main comparison).
Overall completeness and applicability of
evidence
We are confident that our search strategy obtained all available
studies. The results of this review are applicable to all adults under-
going intraocular surgery who would want to make an informed
decision regarding the use of hyaluronidase as an adjunct in eye
blocks to reduce intraoperative pain. We found that the use of
hyaluronidase is beneficial in terms of participant and surgical sat-
isfaction. Such benefit from using hyaluronidase was not statisti-
cally significant with regards to intraoperative reduction of pain.
We consider that most of the authors gave priority to akinesia as
an outcome measure over analgesia, probably due to the perceived
importance for the safe conduct of surgery. This priority has now
receded as the majority of surgeons can carry out most operations
without depending on fully established akinesia. Profound akine-
sia will still be necessary for more difficult operations and training
situations. Hyaluronidase may be necessary to achieve akinesia in
such situations.
Quality of the evidence
We found the overall quality of evidence to be low due imprecision
and inconsistency of the results. There wasmoderate heterogeneity
(I² = 41%). Therefore, we downgraded the quality of evidence by
one level. We looked for possible causes for the variation such as
sample size, dose of hyaluronidase or characteristics of participants
but data were sparse.
We found the overall risk of bias in the studies to be low. However,
therewas anunclear riskwith regards tomethods of randomization
and concealment in a few studies.
As for imprecision, failure to estimate the sample size needed to
make an effect by six of the seven studies led to the quality of
evidence to be downgraded by one level.
Potential biases in the review process
A potential bias arises from the narrow spectrum of the review
question: “Does hyaluronidase improve pain control during eye
surgery?” Hyaluronidase is used for a variety of indications. For
example, if the speed of onset of anaesthesia is increased by
hyaluronidase and the eye is much more akinetic at the beginning
of the operation, participant and surgeon comfortwill also likely be
increased. Therefore, the narrow aspect of analgesia alone does not
consider the full spectrum of beneficial effects from hyaluronidase.
This review found only a relatively small number of studies (seven)
with a small number of participants (500). However, can system-
atic reviews with such sparse data be trusted (Afshari 2017)? Dur-
ing this Cochrane Review, we adhered to all essential requirements
such as publishing a protocol, incorporating risk of bias assess-
ment, searching for unpublished data andmany other review tools
as laid out in the Cochrane framework (Higgins 2011).
According to our protocol, we excluded studies that did not assess
pain in a structured manner (using rating scales). Because of this,
we excluded unstructured assessments that may have shown re-
sults. We consider that results from these trials would have a high
risk of reporting bias and therefore, would not produce a reliable,
useful effect.
Lack of reported data also led to certain included trials being ex-
cluded from the meta-analysis. We were unable to obtain clarifi-
cation about these issues from authors of the included studies.
Readers of this review may be interested in the incidence of ad-
verse effects of hyaluronidase use. Adverse effects such as allergy
to hyaluronidase are extremely rare. None of the trials we anal-
ysed reported any adverse events related to hyaluronidase, but we
would like to highlight that our review would not have reliably
captured the incidence of very rare adverse events due to an overall
small number of participants.
We have acknowledged and taken into account the inherent
methodological limitation of our systematic review and in our
opinion addressed them adequately.
Agreements and disagreements with other
studies or reviews
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Ourfindingsmatch that of the reviewof Schein 2000.Their review
reported the same problems with the available literature that we
found. Those are;
1. very few studies reported data on the effect of hyaluronidase
on pain;
2. high levels of inconsistency among the included studies.
Schein’s review was written in 2000, and despite many additional
studies having been published since, there is still no certainty on
the effect of hyaluronidase use for analgesia.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The requirements for ophthalmic anaesthesia have changed con-
siderably since the early 2000s. Nowadays, the majority of routine
cataract surgery can be conducted pain free under topical anaes-
thesia alone. Injection blocks are used to provide more profound
analgesia for some people and during some operations. The ef-
fects of adding hyaluronidase to local anaesthetic fluid on pain
outcomes in people undergoing eye surgery are uncertain due to
the low quality of the available evidence.
Implications for research
To reach certainty on the question of hyaluronidase use for in-
traoperative analgesia, future studies should separate the various
outcome parameters of speed of onset and akinesia from that of
analgesia.
The importance of pain control is different for anterior and poste-
rior segment eye surgery. This should be looked at in a well pow-
ered randomized controlled trial.
We foundno studies that described the economical impact of using
hyaluronidase. In the current climate of financial restrictions, this
information would be very valuable, and any future study should
incorporate this aspect.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bowman 1997
Methods Parallel group, prospective, masked randomized controlled single centre study in the UK
Study dates not stated.
Participants 92 adults (extracapsular cataract extraction phacoemulsification and trabeculectomy)
received peribulbar block
Number of participants: hyaluronidase group; 44 control group ; 48
Mean age : hyaluronidase group: 72 years; control group : 75 years
Interventions Hyaluronidase group ; lignocaine 2% with adrenaline 1:200,000,
+ bupivacaine 0.5% + hyaluronidase 150 IU/mL.
Control group: lignocaine 2% with adrenaline 1:200,000 + bupivacaine 0.5%
10 mL peribulbar injection using a standardized technique.
Outcomes Akinesia, objective analgesia assessed by surgeon, subjective analgesia assessed by partic-
ipant after surgery
VAS 0 to 10 for subjective and objective pain scores were stratified into a dichotomous
pain/no pain
Notes Conflict of interest and funding sources not documented.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details of randomization described.
Allocation concealment (selection bias) Unclear risk Masked allocation but no details described
Incomplete outcome data (attrition bias)
All outcomes
Low risk No withdrawals reported.
Selective reporting (reporting bias) Low risk All groups were reported on.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Masking of participants described.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double masking described.
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Brydon 1995
Methods Parallel group, randomized double blind design in the UK.
Study dates were not stated.
Participants 60 consecutive adults for elective intra-ocular surgery.
Number of participants: 20 per group. Results for low dose and higher dose were com-
bined for analysis
Mean age: hyaluronidase (low dose) group: 74 years; hyaluronidase (higher dose) group:
73 years; control group: 72 years
Interventions Hyaluronidase (low dose) group: peribulbar block with equal mixture of lignocaine 2%
and bupivacaine 0.75% + hyaluronidase 50 IU/mL
Hyaluronidase (higher dose) group: peribulbar block with equal mixture of lignocaine
2% and bupivacaine 0.75% + hyaluronidase 150 IU/mL
Control group: peribulbar block with equal mixture of lignocaine 2% and bupivacaine
0.75%
No sedation and premedication given.
Outcomes Speed of onset, akinesia, analgesia, top-up frequency, incidence of harm
Analgesia measured by assessing participant’s reaction to insertion of superior rectus
suture and by direct questioning during procedure. 3 point scoring system used. Akinesia
was the primary outcome measure
Notes Conflict of interest and funding sources not documented.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Random assignment but no details de-
scribed.
Allocation concealment (selection bias) Unclear risk Masked allocation but no details described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No withdrawals.
Selective reporting (reporting bias) Low risk All prespecified outcomes reported on.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Composition of the local anaesthetic so-
lution was not known to the anaesthetist”,
but no further details of masking described
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessor (surgeon) masked.
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Khandwala 2008
Methods Parallel group, prospective randomized controlled double masked, single centre trial in
Leeds, the UK
Study dates; not stated.
Participants 20 adults undergoing routine cataract surgery.
Data for 1 participant in hyaluronidase group were incomplete and excluded from anal-
ysis. Participants were ASA 1-3
Number of participants in analysis: hyaluronidase group: 9; control group: 10
Mean age: hyaluronidase group: (73.8 years; control group: 74 years)
Exclusion criteria; refusal, language problems, history of allergy to amide local anaes-
thetics or hyaluronidase or pre-existing extra ocular muscle palsy
Interventions Hyaluronidase group: lignocaine 2% + hyaluronidase 15 IU/mL.
Control group: lignocaine 2%.
Sub-Tenon’s block. Total volume of local anaesthesia 5 mL with no premedication seda-
tion
Outcomes Akinesia, depth of anaesthetic fluid spread on ultrasound, surgical conditions, pain
during operation measured by visual analogue scale (VAS)
SD pain scores unavailable. Attempts to contact authors for more clarification unsuc-
cessful
Notes Authors declared no conflict of interest and received no funding from private or public
bodies
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated randomization.
Allocation concealment (selection bias) Low risk Coded syringes.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 1 participant in treatment group excluded
after randomization, due to incomplete
data
Selective reporting (reporting bias) Low risk All outcomes reported on.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and personnel were masked.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessor masked.
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Remy 2008
Methods Parallel group, prospective randomized double masked placebo controlled trial with a
multicentre design in Germany
Study dates: 29 July 2003 to 2 November 2004.
Participants 80 adults undergoing elective cataract surgery with retrobulbar block. No participant
dropped out
Number of participants: hyaluronidase group: 40; control group: 40
Mean (SD) age: hyaluronidase group: 76 ± 11 years; control group; 74±10 years
Inclusion criteria; adults aged >18 years, elective surgery, no active ocular disease and
informed consent obtained in written form
Exclusion criteria; known intolerance to hyaluronidase, pregnancy, lack of co-operation,
history of alcohol or drug abuse, or local anaesthetic complications
Interventions Hyaluronidase group: 5 mL 1% mepivacaine + 75 IU/mL hyaluronidase
Control group: 5 mL 1%mepivacaine + placebo (special batch of Hyalase without active
ingredient)
Outcomes Primary end point; complete akinesia after 5 minutes.
Secondary end points; akinesia at other times, top-up injections, ptosis, time to anaes-
thesia, pain (VAS) immediately after surgery and 3 hours postsurgery and efficacy and
tolerability for participant and surgeon. Adverse events recorded. First pain assessment
point, planned before surgery then reported for immediately after surgery
Notes No conflict or financial interest reported by author.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomization not described in detail.
Allocation concealment (selection bias) Low risk Double masked as per German legal frame-
work.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No participant dropped out.
Selective reporting (reporting bias) Low risk All outcome measures were reported on.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo control, double masked.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Masked according to federal law.
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Rowley 2000
Methods Parallel group, randomized double masked controlled trial in 1 centre in UK
Study dates: not stated.
Participants 150 adults for elective cataract surgery with sub-Tenon’s block
Number of participants: hyaluronidase group: 76; control group: 74
Mean age; in hyaluronidase group; 77.14 years; control group; 76.51 years
Groups similar in terms of age, sex and proportion of blocks administered by each
investigator
Exclusion criteria: people with learning difficulties, dementia, profound deafness and
known adverse reaction to lignocaine or hyaluronidase
Interventions Hyaluronidase group: 3 mL 2% lignocaine/adrenaline + hyaluronidase 30 IU/mL
Control group: 3 mL 2% lignocaine/adrenaline.
Outcomes Akinesia, post-injection and immediate postoperative pain. Pain measured using VAS
(0-10 cm)
SD pain scores not available with attempts to obtain more clarification from authors
unsuccessful
Notes Declaration of funding sources and conflict of interest not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number tables.
Allocation concealment (selection bias) Low risk Masked syringes.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts.
Selective reporting (reporting bias) Low risk All outcomes reported accordingly.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Masking of participants not described.
Masking of personnel (operative surgeon,
independent assistant and nursing staff )
was described
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double masked design.
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Sedghipour 2012
Methods Parallel group, randomized double masked trial in 1 centre in Iran
Study dates: February 2011 to July 2011.
Participants 44 adults initially recruited froma referral eye centre (Nikookari EyeHospital) to undergo
elective cataract surgery (phacoemulsification) under sub-Tenon block. 2 participants
did not meet the criteria and were excluded
Number of participants: hyaluronidase group: 21; control group: 21
Mean (SD) ages: hyaluronidase group: 65.62 ± 3.01 years; control group; 67 ± 4.4 years
Groups comparable for gender and age.
Exclusion criteria: people with deafness and allergy to lidocaine or hyaluronidase
Interventions Hyaluronidase group: 2 mL 2% lidocaine + hyaluronidase 150 IU/mL
Control group: 2 mL 2% lidocaine.
Ampoules were identical in appearance with a printed code (A or B)
Codes disclosed for statistical analysis only at end of study
Outcomes Akinesia, participant and surgical satisfaction with yes/no questions, postoperative pain
via VAS scoring using a standard VAS chart. Participants were given appropriate expla-
nation on usage of chart
Notes No declaration of funding sources or conflict of interest reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Consecutive numbers assigned to partici-
pants on admission by a staff member not
involved in study
Allocation concealment (selection bias) Low risk Coded syringes.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No exclusions after randomization re-
ported.
Selective reporting (reporting bias) Low risk All outcomes reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Masking of participants, personnel by
coded syringes.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessor masked by coded syringes.
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Shiroma 2002
Methods Randomized double masked study conducted at State University of Campinas - Uni-
camp, Brazil
Study dates: not stated.
Participants 57 adults undergoing elective extracapsular cataract extraction on an outpatient basis.
Participant’s physical statuses described as ASA 1- 3
Number of participants: hyaluronidase group: 29; control group: 28
Sex: 31 men (54.4%); 26 women (45.6%).
Age range (overall): 45- 89 years; mean (SD) overall: 67.73 (± 10.65)
Groups homogeneous in relation to sex, age and physical condition
Peribulbar injection given as a block by double needle injection with 25x7 mm needle,
administered 4mLat lower temporal with super-medial inclinationof about 15°and3mL
(nasal-superior). Anaesthetic solution prepared without knowledge of ophthalmologist
who performed the block
Interventions Hyaluronidase group: ropivacaine 1% + hyaluronidase 100 IU/mL
Control group: ropivacaine 1%.
Outcomes Onset time to akinesia, need for supplementary injections and pain assessed by VAS (0-
10)
Notes No declaration of funding sources or conflict of interest reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomization not specified.
Allocation concealment (selection bias) Unclear risk Allocation concealment not described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No withdrawals documented, all partici-
pants included initially were assessed and
reported
Selective reporting (reporting bias) Low risk Primary outcomes reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Masking described in participants and per-
sonnel.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessment masked.
ASA: American Society of Anesthesiology Classification; SD: standard deviation; VAS: visual analogue scale.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Berg 2001 Pain not assessed formally using a rating scale. Instead, augmentation eye drops given if participant complained
of pain during procedure. Therefore, pain not measured but reported
Crawford 1994 2 participants in the hyaluronidase group received local anaesthetic drops for pain intraoperatively. However,
pain not formally measured, therefore, inclusion criteria not met
Guise 1999 Pain not formally measured using a rating scale.
House 1991 Pain not measured as per rating scale and top-ups primarily given to achieve akinesia initially
Johansen 1993 Surgeon assessed quality of analgesia and pain, not measured by asking participant. No formal method of
assessing pain described
Lange 1989 On further inspection, not a randomized trial.
Moharib 2002 Adequate pain relief defined as lack of complaint or response from participant. Did not constitute pain mea-
surement and no formal assessment of pain described in the study
Morsman 1992 Presence or absence of hyaluronidase not masked.
Ramanathan 1999 Poster presentation, Further details could not be obtained about randomization, masking and results
Sarvela 1992 Part one of third study was not randomized. Part two of this study compared two different concentrations of
hyaluronidase only
Soares 2002 Intraoperative pain not measured (e.g. by asking participant). It was assumed that the participants would spon-
taneously voice their pain during operation. Therefore, study did not measure any of our stipulated outcomes
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D A T A A N D A N A L Y S E S
Comparison 1. Hyaluronidase versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Intraoperative pain (reported
continuous)
3 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
2 Intraoperative pain (reported
dichotomous)
4 289 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.48, 1.42]
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Entering data into Review Manager (5): KA and HR.
Review Manager 5 statistical data: KA, HR and CB.
Other statistical analysis not using Review Manager 5: CB.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We made the following changes to the protocol (Rüschen 2013);
1. This review included only adults, we therefore stated “adults” in the title.
2. The phrase ’to reduce intraoperative pain’ was added to the title to comply with PICO to reflect the review question.
3. Lee Adams was initially a registered author, but gave his agreement to be removed from the authors list at the protocol stage.
4. We added Kavitha Aravinth as second author.
5. We added Desta Bokre as fourth author.
6. We further stated in the primary objective that when considering studies for inclusion that we excluded studies that did not
measure pain with a rating scale because spontaneous reporting of pain by the participant is not likely to produce reproducible results.
7. We stated the secondary objectives (incidence of harm, participant and surgical satisfaction and economic outcomes or cost
calculations) in the Objectives section.
8. We stated in the protocol that intraoperative pain would be recorded using (VAS); however, we observed that included studies
used either (VAS) or (VRS) to rate pain. As both are accepted and validated tools to measure pain, we analysed both these methods of
measuring pain in the same manner.
9. We initially proposed to include only studies that described the first eye operation, but during the review process, we found no
publication that described if the participants had a first or second eye operation.(See Types of participants and Unit of analysis issues).
10. We excluded adnexal surgery and any other eye surgery that was not intraocular. Anaesthetic techniques and surgical
interventions for adnexal operations are inherently different from intraocular surgery and produce a very different pain profile.
11. We used GRADE-pro to analyse the quality of evidence and to produce a ’Summary of Findings table’.
12. Collation of references: we added the following to the Selection of studies section. “Where studies had multiple publications, we
planned to collate the reports of the same study so that each study, rather than each report, was the unit of interest for the review and
such studies had a single identifier with multiple references.
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